Skip to main navigation Skip to search Skip to main content

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

  • El Chaer, F. (Speaker)
  • Additional Authors and Affiliations (Speaker)

Activity: Talk or presentation › Oral presentation

Description

ASH, New Orleans, LA.
Period2022
Held atAmerican Society of Hematology (ASH)